PharmNovo reports promising preclinical results on abuse potential and withdrawal symptom relief
PharmNovo, a Swedish pharmaceutical company developing neuropathic pain treatment, today announces promising preclinical results for drug candidate PN6047. The candidate does not show abuse potential in animal models and also indicates a capacity to reduce opioid withdrawal symptoms. The results reinforce the candidate's safety profile ahead of 2024 clinical phase II trials.The drug candidate PN6047 from PharmNovo is a new type of selective delta opioid receptor agonist. It is intended to provide safe and effective neuropathic pain relief without the adverse side effects of conventional